Search Results 251-260 of 19298 for prostate cancer
Metastatic castration-resistant prostate cancer presents treatment challenges, including the side effects of chemotherapy. Mayo Clinic researchers find that ...
Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. · More about research at Mayo Clinic.
... prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It is given in patients with suspected metastasis (cancer that has ...
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
Prostate cancer research is conducted in coordination with Mayo Clinic Comprehensive Cancer Center. Mayo Clinic Comprehensive Cancer Center receives funding ...
... prostate cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells ...
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).
However, cancer is just one of several possible causes of increased prostate-specific antigen levels. After any procedure for an enlarged prostate, a number of ...
Learn about this procedure used to treat urinary problems caused by an enlarged prostate gland.
About this study. A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Benefactor support fuels Mayo Clinic’s groundbreaking research. Make a gift today to help us save lives.